Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis

BACKGROUND: Pancreatic cancer is mostly diagnosed in an advanced stage and treated with systemic therapy with palliative intent. Nowadays, the doublet chemotherapy of Gemcitabine and nab‐paclitaxel (Gem‐Nab) is one of the most frequently used regimens worldwide, but is not ubiquitarily available or...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlick, Konstantin, Gantschnigg, Antonia, Seymer, Alexander, Huemer, Florian, Greil, Richard, Weiss, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501299/
https://www.ncbi.nlm.nih.gov/pubmed/37537780
http://dx.doi.org/10.1002/cam4.6334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501299/
https://www.ncbi.nlm.nih.gov/pubmed/37537780
http://dx.doi.org/10.1002/cam4.6334

Ejemplares similares